ArticleCancer cytopathology2021
Cytopathology practice during the COVID-19 postlockdown: An Italian experience.
Article in Cancer cytopathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- COVID-19's Shadow: The Effect of COVID-19 on Cytopathology Specimens Received at an Academic Laboratory in Central South Africa.Cytopathology : official journal of the British Society for Clinical Cytology · 2026Article
- Impact of the COVID-19 Pandemic on Thyroid Cancer Surgery.Current oncology (Toronto, Ont.) · 2024Article
- Article
- Impact of COVID-19 Pandemic on Thyroid Surgery in a University Hospital in South Korea.Cancers · 2022Article
- Cancer diagnosis in Catalonia (Spain) after two years of COVID-19 pandemic: an incomplete recovery.ESMO open · 2022Article
- COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study.Cancer cytopathology · 2022Article
- Importance of Cytopathologic Diagnosis in Early Cancer Diagnosis in Resource-Constrained Countries.JCO global oncology · 2022Review
- Cytopathology practice during the COVID-19 postlockdown: An Italian experience.Cancer cytopathology · 2021Article
- Effects of COVID-19 pandemic on cytology: specimen adequacy in fine-needle aspiration of palpable head and neck masses.Journal of the American Society of CytopathologyArticle
- Does ROSE matter? Evaluation of final diagnostic, PD-L1 immunohistochemistry, and molecular testing yields of CT-guided lung biopsies performed before and after the onset of the COVID-19 pandemic.Journal of the American Society of CytopathologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDuring the current coronavirus disease 2019 (COVID-19) pandemic, the cytopathology workload has decreased remarkably worldwide as all screening and elective procedures have been postponed to prioritize the clinical management of patients at high oncological risk. In the current study, the authors provide data on the lasting impact of COVID-19 on cytopathology practice during the initial phases of the Italian postlockdown period.
methodsThe percentages of the cytological sample types processed at the University of Naples Federico II during the first 12 weeks of the Italian postlockdown period were compared with those of the same period in 2019. The study period was divided into four 3-week periods. Differences in the rates of malignant diagnoses were also assessed.
resultsDuring the 12-week study period, the overall cytological sample workload decreased by 41.6% in comparison with 2019. In particular, the workload significantly declined for each sample type: Pap smears, -33.3%; urine, -42.8%; serous fluids, -14.4%; thyroid, -54.5%; breast, -43%; lymph node, -27.3%; and salivary gland, -61%. By contrast, the overall malignancy rate was significantly increased (P = .0011).
conclusionsThe reduction in the cytological sample workload during the postlockdown period still represents an ongoing effect of the COVID-19 pandemic. On the other hand, the rise in the overall malignancy rate reflects the importance of prioritizing diagnostic procedures for patients at high oncological risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.